Catalent, Inc.

CTLT

US1488061029

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:01 2024-04-23 pm EDT			5-day change	1st Jan Change
56.03 ^USD	-0.04%		+0.45%	+24.71%

Apr. 12	Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48	MT
Apr. 08	Sector Update: Health Care Stocks Decline Late Afternoon	MT

Catalent, Inc. acquired Biologics development and manufacturing facility of VMIC Ltd.

April 05, 2022

Catalent, Inc. (NYSE:CTLT) acquired Biologics development and manufacturing facility of VMIC Ltd on April 6, 2022. Peter Jennings, David Willott and Sean Croston of Grant Thornton Corporate Finance acted as financial advisor to Vaccine Manufacturing And Innovation Centre Uk Limited

Catalent, Inc. (NYSE:CTLT) completed the acquisition of Biologics development and manufacturing facility of VMIC Ltd on April 6, 2022.

Latest news about Catalent, Inc.

Zacks Investment Research Downgrades Catalent to Underperform From Neutral, Price Target is $48	Apr. 12	MT
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 08	MT
Sector Update: Health Care Stocks Flat to Higher Premarket Monday	Apr. 08	MT
Novo Nordisk Parent Resubmits US Antirust Application for Catalent Acquisition	Apr. 08	MT
Novo Nordisk parent refiles US application on Catalent deal	Apr. 08	RE
Novo Nordisk owner refiles U.S. application for approval of Catalent deal	Apr. 08	RE
Invenra Inc. Announces Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs	Apr. 02	CI
Novo Nordisk hopes to launch experimental obesity drug this decade	Mar. 08	RE
Transcript : Catalent, Inc. - Special Call	Mar. 07
European stocks hover near record highs at start of busy week	Mar. 04	RE
Wegovy packing supplier Catalent lays off 300 workers	Feb. 14	RE
Novo Holdings to Invest up to $7 Billion a Year by 2030	Feb. 12	MT
Novo Holdings to Invest up to $7 Billion a Year by 2030	Feb. 12	MT
Catalent Swings to Fiscal Q2 Adjusted Loss as Revenue Declines	Feb. 09	MT
Earnings Flash (CTLT) CATALENT Posts Q2 Revenue $1.03B, vs. Street Est of $1.01B	Feb. 09	MT
Catalent, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 09	CI
North American Morning Briefing : Stock Futures Rise; S&P 500 Again Tests 5,000 Milestone	Feb. 09	DJ
Global markets live: Kering, Publicis, Paypal, Mattel, Nvidia...	Feb. 08
Astrazeneca says Catalent deal shows importance of in-house capacity	Feb. 08	RE
European Medicines Agency to Look Into Novo Nordisk's Acquisition of Catalent Sites	Feb. 08	MT
US FDA finds control lapses at Catalent plant being sold to Novo	Feb. 07	RE
EU watchdog is looking into availability of drugs made at Catalent sites sold to Novo	Feb. 07	RE
EU watchdog to assess availability of drugs made at Catalent sites sold to Novo	Feb. 07	RE
Eli Lilly Calls for Regulatory Scrutiny of Novo Holding's Catalent Deal	Feb. 07	MT
US Regulator Finds Lapses at Novo Nordisk Supplier Catalent's Factory	Feb. 06	MT

Chart Catalent, Inc.

Duration

Period

More charts

Company Profile

Catalent, Inc. is specialized in pharmaceutical outsourcing services. The group offers solutions for the development and formulation of drugs, biological products and animal health products. Net sales break down by activity as follows: - provision of development services and clinical supply services (55.4%); - subcontracted manufacturing services (44.6%). Net sales are distributed geographically as follows: the United States (63.2%), Europe (28.7%) and other (8.1%).

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q3 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Catalent, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

56.05 USD

Average target price

63.5 USD

Spread / Average Target

+13.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CATALENT, INC.	+24.71%	10.14B
ELI LILLY AND COMPANY	+27.92%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.59%	359B
MERCK & CO., INC.	+16.38%	322B
ABBVIE INC.	+9.39%	297B
ASTRAZENECA PLC	+6.30%	215B
NOVARTIS AG	+4.80%	210B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.58%	149B

Other Pharmaceuticals

Catalent, Inc.

Equities

CTLT

US1488061029

Pharmaceuticals

Catalent, Inc. acquired Biologics development and manufacturing facility of VMIC Ltd.

EPS Revisions